← Leaderboards
Anna Wald
University Of Washington
$34,443,936
Attributed
$49,446,857
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.9M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$90,106,131 · 24
By mechanism
U19$28,580,302 · 9
P01$26,095,572 · 7
UM1$25,421,603 · 1
R01$4,584,240 · 1
T32$2,796,954 · 1
K24$1,696,438 · 1
Top collaborators
- Raymond Scott Mcclelland13 shared
- Margaret M Madeleine10 shared
- Helen Ying-Hui Chu1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Christina M Marra$12,495,867
- Lorenzo Giacani$8,553,035
- Sheila A. Lukehart$22,581,544
- Lisa E Manhart$10,223,947
- Glaber Arturo Centurion-Lara$935,164
Others in their field
Top investigators on “Simplexvirus”
- David Leung · National Jewish Health$31,859,607
- Daniel F. Hoft · Saint Louis University$26,271,892
- Thomas Denny · Duke University$23,095,705
- Homayon Ghiasi · Cedars-Sinai Medical Center$19,611,810
- David M Knipe · Harvard Medical School$18,668,685
- David A. Leib · Dartmouth College$16,757,687
Research focus
SimplexvirusLaboratoriesVaccinesPersonsUniversitiesWashingtonClinical ResearchSexually Transmitted DiseasesInfectionResearch PersonnelEnrollmentSiteClinicGenital HerpesBiopsySamplingImmune ResponseClinical TrialsParticipantGenital SystemWomanReportingPathogenesisLesion
Grant awards (117)
University of Washington Vaccine and Treatment Evaluation Unit$2,527,789
UM1 · FY2025 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$2,579,381
UM1 · FY2024 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$2,008,543
U19 · FY2023 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$1,863,350
UM1 · FY2023 · AI · contact PI
STD and AIDS Research Training Grant$721,965
T32 · FY2023 · AI · contact PI
Administrative Core$382,811
U19 · FY2023 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$153,954
U19 · FY2023 · AI · contact PI
Clinical and Statistical Core$144,944
U19 · FY2023 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$123,665
U19 · FY2023 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$2,038,924
U19 · FY2022 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$1,561,928
UM1 · FY2022 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$780,737
R01 · FY2022 · CA
STD and AIDS Research Training Grant$703,251
T32 · FY2022 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$621,600
UM1 · FY2022 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$345,560
UM1 · FY2022 · AI · contact PI
Administrative Core$330,151
U19 · FY2022 · AI · contact PI
Administrative Core$123,665
U19 · FY2022 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$111,108
UM1 · FY2022 · AI · contact PI
Clinical and Statistical Core$95,436
U19 · FY2022 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$2,516,717
UM1 · FY2021 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$2,081,657
U19 · FY2021 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012$1,259,301
UM1 · FY2021 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit -- DMID 20-0034$734,126
UM1 · FY2021 · AI · contact PI
STD and AIDS Research Training Grant$688,601
T32 · FY2021 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$625,251
UM1 · FY2021 · AI · contact PI
Administrative Core$435,954
U19 · FY2021 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$427,640
UM1 · FY2021 · AI · contact PI
Clinical and Statistical Core$266,865
U19 · FY2021 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$227,161
R01 · FY2021 · CA
University of Washington Vaccine and Treatment Evaluation Unit$9,616,028
UM1 · FY2020 · AI · contact PI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$2,090,181
U19 · FY2020 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$765,488
R01 · FY2020 · CA
STD and AIDS Research Training Grant$683,137
T32 · FY2020 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$631,824
UM1 · FY2020 · AI · contact PI
Administrative Core$455,439
U19 · FY2020 · AI · contact PI
Clinical and Statistical Core$285,407
U19 · FY2020 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$251,374
R01 · FY2020 · CA
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$134,231
R01 · FY2020 · CA
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection$2,145,755
U19 · FY2019 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$707,409
R01 · FY2019 · CA
Administrative Core$305,477
U19 · FY2019 · AI · contact PI
Clinical and Statistical Core$178,069
U19 · FY2019 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$108,522
R01 · FY2019 · CA
University of Washington Sexually Transmitted Infections Cooperative Research Cen$3,135,008
U19 · FY2018 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$753,320
R01 · FY2018 · CA
Clinical & Laboratory Core$337,505
U19 · FY2018 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$88,149
R01 · FY2018 · CA
University of Washington Sexually Transmitted Infections Cooperative Research Cen$2,710,804
U19 · FY2017 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,535,398
P01 · FY2017 · AI · contact PI
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial$767,849
R01 · FY2017 · CA
Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: an Inception Cohor$704,769
P01 · FY2017 · AI · contact PI
Clinical & Laboratory Core$402,717
U19 · FY2017 · AI · contact PI
Administrative Core$218,655
P01 · FY2017 · AI · contact PI
University of Washington Sexually Transmitted Infections Cooperative Research Cen$2,832,119
U19 · FY2016 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,520,298
P01 · FY2016 · AI · contact PI
Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: an Inception Cohor$812,218
P01 · FY2016 · AI · contact PI
Administrative Core$213,338
P01 · FY2016 · AI · contact PI
Clinical & Laboratory Core$186,870
U19 · FY2016 · AI · contact PI
University of Washington Sexually Transmitted Infections Cooperative Research Cen$2,824,774
U19 · FY2015 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,529,656
P01 · FY2015 · AI · contact PI
Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: an Inception Cohor$809,621
P01 · FY2015 · AI · contact PI
Clinical & Laboratory Core$290,420
U19 · FY2015 · AI · contact PI
Administrative Core$217,961
P01 · FY2015 · AI · contact PI
Clinical Research in HSV Infections$182,894
K24 · FY2015 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,420,948
P01 · FY2014 · AI · contact PI
Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: an Inception Cohor$572,248
P01 · FY2014 · AI · contact PI
Clinical & Laboratory Core$356,202
U19 · FY2014 · AI · contact PI
Administrative Core$253,281
P01 · FY2014 · AI · contact PI
Clinical Research in HSV Infections$182,894
K24 · FY2014 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,417,953
P01 · FY2013 · AI · contact PI
Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: an Inception Cohor$669,050
P01 · FY2013 · AI · contact PI
Administrative Core$230,980
P01 · FY2013 · AI · contact PI
Clinical Research in HSV Infections$182,894
K24 · FY2013 · AI · contact PI
The gender specific prevalence of multiple strain genital HSV-2 infection$181,538
R21 · FY2013 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,021,461
P01 · FY2012 · AI · contact PI
Prevention of HSV Morbidity in Pregnancy and the Newborn$339,230
P01 · FY2012 · AI · contact PI
Clinical Core$237,468
P01 · FY2012 · AI · contact PI
The gender specific prevalence of multiple strain genital HSV-2 infection$231,750
R21 · FY2012 · AI · contact PI
Clinical Research in HSV Infections$182,894
K24 · FY2012 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,023,902
P01 · FY2011 · AI · contact PI
Prevention of HSV Morbidity in Pregnancy and the Newborn$278,600
P01 · FY2011 · AI · contact PI
Clinical Core$267,671
P01 · FY2011 · AI · contact PI
Clinical Research in HSV Infections$182,894
K24 · FY2011 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,044,274
P01 · FY2010 · AI · contact PI
Prevention of HSV Morbidity in Pregnancy and the Newborn$163,639
P01 · FY2010 · AI · contact PI
Clinical Research in HSV Infections$162,573
K24 · FY2010 · AI · contact PI
Clinical Core$157,197
P01 · FY2010 · AI · contact PI
Prevention of HSV Morbidity in Pregnancy and the Newborn$166,023
P01 · FY2009 · AI · contact PI
Clinical Core$159,487
P01 · FY2009 · AI · contact PI
Clinical Research in HSV Infections$159,411
K24 · FY2009 · AI · contact PI
Immunogenetic Correlates of Severity of Genital HSV-2$305,397
U19 · FY2008 · AI · contact PI
Prevention of HSV Morbidity in Pregnancy and the Newborn$171,727
P01 · FY2008 · AI · contact PI
Clinical Research in HSV Infections$156,342
K24 · FY2008 · AI · contact PI
Clinical Core$149,215
P01 · FY2008 · AI · contact PI
Immunogenetic Correlates of Severity of Genital HSV-2$282,775
U19 · FY2007 · AI · contact PI
Clinical Research in HSV Infections$153,360
K24 · FY2007 · AI · contact PI
HALF-LIFE AND PATTERN OF RESOLUTION OF HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)$533
M01 · FY2007 · RR · contact PI
Immunogenetic Correlates of Severity of Genital HSV-2$339,275
U19 · FY2006 · AI · contact PI
Clinical Research in HSV Infections$150,282
K24 · FY2006 · AI · contact PI
HALF-LIFE AND PATTERN OF RESOLUTION OF HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)$43,002
M01 · FY2006 · RR · contact PI
Immunogenetic Correlates of Severity of Genital HSV-2$331,156
U19 · FY2005 · AI
Treatment of Acute Hepatitis C in Injection Drug Users$149,605
R21 · FY2005 · DA
SHEDDING AFTER BEGINNING ACYCLOVIR TREATMENT HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)$21,394
M01 · FY2005 · RR
Immunogenetic Correlates of Severity of Genital HSV-2$292,483
U19 · FY2004 · AI
Treatment of Acute Hepatitis C in Injection Drug Users$151,600
R21 · FY2004 · DA
Treatment of Acute Hepatitis C in Injection Drug Users$151,600
R21 · FY2003 · DA
CORE--CLINICAL$228,401
P01 · FY2002 · AI
BIOLOGY AND EPIDEMIOLOGY OF GENITAL HSV ACQUISITION$228,401
P01 · FY2002 · AI
HUMAN HERPESVIRUS 8--EPIDEMIOLOGY AND NATURAL HISTORY$0
U19 · FY2002 · AI
CORE--CLINICAL$0
P01 · FY2001 · AI
HUMAN HERPESVIRUS 8--EPIDEMIOLOGY AND NATURAL HISTORY$0
U19 · FY2001 · AI
BIOLOGY AND EPIDEMIOLOGY OF GENITAL HSV ACQUISITION$0
P01 · FY2001 · AI
CORE--CLINICAL$166,251
P01 · FY2000 · AI
BIOLOGY AND EPIDEMIOLOGY OF GENITAL HSV ACQUISITION$166,251
P01 · FY2000 · AI
HUMAN HERPESVIRUS 8--EPIDEMIOLOGY AND NATURAL HISTORY$152,950
U19 · FY2000 · AI
HUMAN HERPESVIRUS 8--EPIDEMIOLOGY AND NATURAL HISTORY$152,950
U19 · FY2000 · AI
HUMAN HERPESVIRUS 8--EPIDEMIOLOGY AND NATURAL HISTORY$0
U19 · FY2000 · AI